STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Clinical trials for STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental triple therapy takes on head and neck cancer
Disease control OngoingThis early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…
Matched conditions: STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Matched conditions: STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: STAGE IV HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC